Register for our free email digests:
Latest From 4-Antibody AG
Biotechnology companies and their investors came back from summer break with a slew of venture capital funding rounds and a royalty deal, although it remains to be seen how many early-stage firms will remain financially independent with large biotech and pharmaceutical companies raising massive stockpiles of cash.
Amgen moves into the chimeric antigen receptor T-cell space in cancer under a complex partnership with Kite Pharma. Gilead, Isis and Janssen agree to multiple deals during and after the holiday season, while scuttled deals return assets or rights to Vanda, AMAG and OncoGenex.
Incyte will pay Agenus $60m up front and $350m in development, regulatory and commercial milestone fees to license the Retrocyte Display antibody discovery platform for the development of novel immunotherapies. The upfront fee is comprised of a $25m technology and program access fee as well as a $35m equity investment at $4.51 per share.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Cavadis BV
- Senior Management
- Heico Breek, MD, CEO
- Contact Info
Phone: (31) 653279243
Kamer EE 19-14
P.O. Box 2040 Rotterdam, 3000
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.